CA3118327A1 - Acides nucleiques permettant d'inhiber l'expression de l'aldh2 dans une cellule - Google Patents

Acides nucleiques permettant d'inhiber l'expression de l'aldh2 dans une cellule Download PDF

Info

Publication number
CA3118327A1
CA3118327A1 CA3118327A CA3118327A CA3118327A1 CA 3118327 A1 CA3118327 A1 CA 3118327A1 CA 3118327 A CA3118327 A CA 3118327A CA 3118327 A CA3118327 A CA 3118327A CA 3118327 A1 CA3118327 A1 CA 3118327A1
Authority
CA
Canada
Prior art keywords
strand
nucleic acid
nucleotides
modified
rna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3118327A
Other languages
English (en)
Inventor
Sibylle DAMES
Ute SCHAEPER
Steffen Schubert
Stephan TENBAUM
Lucas Bethge
Christian Frauendorf
Judith HAUPTMANN
Adrien Weingartner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Silence Therapeutics GmbH
Original Assignee
Silence Therapeutics GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP17201447.4A external-priority patent/EP3483269A1/fr
Application filed by Silence Therapeutics GmbH filed Critical Silence Therapeutics GmbH
Publication of CA3118327A1 publication Critical patent/CA3118327A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y102/00—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2)
    • C12Y102/01—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2) with NAD+ or NADP+ as acceptor (1.2.1)
    • C12Y102/01003—Aldehyde dehydrogenase (NAD+) (1.2.1.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/343—Spatial arrangement of the modifications having patterns, e.g. ==--==--==--
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol

Abstract

La présente invention concerne des produits et des compositions ainsi que leurs utilisations. En particulier, l'invention concerne des produits acides nucléiques qui interfèrent avec l'expression du gène de l'ALDH2 ou inhibent son expression et des utilisations thérapeutiques telles que pour le traitement ou la prévention du trouble de la consommation d'alcool.
CA3118327A 2017-11-13 2018-11-13 Acides nucleiques permettant d'inhiber l'expression de l'aldh2 dans une cellule Pending CA3118327A1 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP17201447.4A EP3483269A1 (fr) 2017-11-13 2017-11-13 Produits et compositions
EP17201447.4 2017-11-13
EP18179176.5 2018-06-21
EP18179176.5A EP3483272A1 (fr) 2017-11-13 2018-06-21 Produits et compositions
GB1815921.0 2018-09-28
GB201815921 2018-09-28
PCT/EP2018/081105 WO2019092282A1 (fr) 2017-11-13 2018-11-13 Acides nucléiques permettant d'inhiber l'expression de l'aldh2 dans une cellule

Publications (1)

Publication Number Publication Date
CA3118327A1 true CA3118327A1 (fr) 2019-05-16

Family

ID=66437599

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3118327A Pending CA3118327A1 (fr) 2017-11-13 2018-11-13 Acides nucleiques permettant d'inhiber l'expression de l'aldh2 dans une cellule

Country Status (3)

Country Link
EP (1) EP3735461A1 (fr)
CA (1) CA3118327A1 (fr)
WO (1) WO2019092282A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3710586T (lt) 2017-11-13 2023-02-27 Silence Therapeutics Gmbh Nukleorūgštis, skirta slopinti lpa raišką ląstelėje
US11661603B2 (en) 2018-01-16 2023-05-30 Dicerna Pharmaceuticals, Inc. Compositions and methods for inhibiting ALDH2 expression
JP7245328B2 (ja) * 2018-11-13 2023-03-23 サイレンス・セラピューティクス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 細胞におけるｌｐａの発現を抑制するための核酸
JP2022526419A (ja) * 2019-04-04 2022-05-24 ディセルナ ファーマシューティカルズ インコーポレイテッド 中枢神経系における遺伝子発現を阻害するための組成物及び方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL9201440A (nl) 1992-08-11 1994-03-01 Univ Leiden Triantennaire clusterglycosiden, hun bereiding en toepassing.
RU2014117690A (ru) * 2011-10-05 2015-11-10 Протива Байотерапьютикс Инк. Композиции и способы для сайленсинга альдегид-дегидрогеназы
EP3228326A1 (fr) 2016-04-05 2017-10-11 Silence Therapeutics GmbH Acide nucléique lié à un glycoconjugué trivalent

Also Published As

Publication number Publication date
WO2019092282A1 (fr) 2019-05-16
EP3735461A1 (fr) 2020-11-11

Similar Documents

Publication Publication Date Title
CA3081905C (fr) Acides nucleiques permettant d'inhiber l'expression de lpa dans une cellule
US11499153B2 (en) Nucleic acids for inhibiting expression of LPA in a cell
WO2019193144A1 (fr) Siarns avec vinylphosphonate à l'extrémité 5' du brin antisens
CA3118327A1 (fr) Acides nucleiques permettant d'inhiber l'expression de l'aldh2 dans une cellule
EP4029942A1 (fr) Produits et compositions
WO2018185253A1 (fr) Acides nucléiques bicaténaires modifiés par un ligand
CA3095523A1 (fr) Siarns avec vinylphosphonate a l'extremite 5' du brin antisens
WO2019092280A1 (fr) Acides nucléiques pour inhiber l'expression d'un gène cible comprenant des liaisons phosphorodithioate
EP3775209A1 (fr) Arnsi possédant au moins deux ligands à deux extrémités distinctes
EP3550022A1 (fr) Produits et compositions
EP3483272A1 (fr) Produits et compositions